Our Portfolio 

Our portfolio reflects the scale and diversity of the broader healthcare venture capital market.


For over 13 years, we have created customized solutions for venture funds, corporate venture funds, limited partnership interests, operating companies, and individual shareholders.


Labcyte Inc. is a laboratory instrumentation company with a novel approach to dispensing small volumes of liquids for life sciences applications. It was acquired by Beckman Coulter Life Sciences in 2019.

Adaptive Biotechnologies is a leader in immune-driven medicine. IPO in 2019, NASDAQ: ADPT.

Torax Medical, Inc. develops and markets products designed to treat sphincter disorders utilizing its technology platform, Magnetic Sphincter Augmentation (MSA). It was acquired by Johnson & Johnson's Ethicon in 2017.

SurgiQuest Inc. develops, manufactures and markets innovative access technologies for minimally invasive surgery. It was acquired by ConMed in 2016.

ClearCorrect is a clear aligner system used to straighten teeth as an alternative to traditional braces. It was acquired by Straumann Group in 2017.


Veran's SPiN Thoracic Navigation System® is revolutionizing bronchoscopy and transforming the standard of care for early lung cancer diagnoses.


DiscoverX provides innovative cell-based assays and services for drug discovery and development. It was acquired by Eurofins Pharma Discovery Services (EPDS) in 2017.

Crescendo Bioscience develops diagnostic tools for rheumatologists to manage patients with autoimmune and inflammatory diseases. It was acquired by Myriad Genetics in 2014.

Corventis is a pioneer in wearable, wireless technologies for cardiac disease. It was acquired by Medtronic in 2014. 

Pulsar Vascular Inc developed the PulseRider minimally invasive, self-expanding nitinol implant. It was acquired by Codman Neuro in 2016.

Endologix, Inc. is singularly focused on providing innovative, minimally invasive technologies for aortic disorders. IPO in 2018 (NASDAQ: ELGX)​​.


TransMedics, Inc. is a medical device company founded to address the unmet need for more and better organs for transplantation. IPO in 2019 (NASDAQ: TMDX​). 

Akebia is focused on the development of therapeutics based on hypoxia-inducible factor biology. IPO in 2014 (NASDAQ: AKBA).


NOVADAQ is a leading developer of fluorescence imaging technology. It was acquired by Stryker Corporation in 2017.


Wellpartner is a leading provider of 340B Drug Pricing Program services It was acquired by CVS Health in 2018. 


Counsyl is a health technology company that offers DNA screening for men, women, and their children. It was acquired by Myriad Genetics in 2018.


ViewRay, Inc. designs, manufactures, and markets the MRIdian® radiation therapy system. IPO in 2015 (NASDAQ: VRAY​).

Esperion Therapeutics 

focuses on the development of bempedoic acid. IPO in 2013 (NASDAQ: ESPR).

iRhythm is a digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed. IPO in 2016 (NASDAQ: IRTC).

Liquidia is a late-stage clinical biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary PRINT® technology.

ASC logo.png

 Advanced Surgical Concepts focuses on offering a high quality, service oriented environment for surgical procedures. 


QuatRx is focused on development of therapeutics for endocrine and metabolic diseases. It was acquired by Shionogi Pharma Inc. in 2017.

Aerpio Pharmaceuticals focuses on  leveraging Tie2 activation for ocular disease and vascular stabilization. IPO in 2018 (NASDAQ: ARPO).

AcelRx Pharmaceuticals  focuses on the development and commercialization of innovative therapies. IPO in 2011 (NASDAQ: ACRX).

Revelation Partners_Logo-01.png

255 California Street

12th Floor

San Francisco, CA 94111

Tel: 415-905-7226

  • LinkedIn

© 2020 by Revelation Partners